Is Relay Therapeutics Inc (NASDAQ: RLAY) No Longer A Good Investment?

After Hours

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Most recently, Yahoo Finance reported about the stock as it publicized that Relay Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Stocks Info

RLAY belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. The current market capitalization of Relay Therapeutics Inc is $1.21B. A total of 1.17 million shares were traded on the day, compared to an average of 1.17 shares.

Insider Activity

Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, RLAY has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 4 BUYs and 29 SELLs from insiders. Insiders purchased 166,370 shares during that period but sold 44,605.

In the most recent transaction, Bergstrom Donald A sold 3,178 shares of RLAY for 9.64 per share on Jan 29. After the transaction, the President, R&D now owns 530,878 company shares. In a previous transaction on Jan 29, Catinazzo Thomas sold 2,005 shares at 9.64 per share. RLAY shares that Chief Financial Officer owns now total 341,846.

Among the insiders who sold shares, Adams Brian disposed of 1,929 shares on Jan 29 at a per-share price of $9.64. This resulted in the Chief Legal Officer holding 327,738 shares of RLAY after the transaction. In another insider transaction, Rahmer Peter sold 1,651 shares at $9.64 per share on Jan 29. Company shares held by the insider now total 514,977.

While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for RLAY in the last 3 months, the mean price target is $22.51 with high estimates of $33.00 and low estimates of $10.60. In terms of 52-week highs and lows, RLAY has a high of $20.13 and a low of $5.95.

As of this writing, RLAY has an earnings estimate of -$0.73 per share for the current quarter. EPS was calculated based on a consensus of 11 estimates, with a high estimate of -$0.41 per share and a lower estimate of -$0.79. The company reported an EPS of -$0.81 in the last quarter, which was 1.20% higher than expectations of -$0.82.

Balance Sheet Annually/Quarterly

An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. RLAY’s latest balance sheet shows that the firm has $958.07M in Cash & Short Term Investments as of fiscal 2021. There were $22.90M in debt and $24.32M in liabilities at the time. Its Book Value Per Share was $6.32, while its Total Shareholder’s Equity was $897.81M.

Analysts Opinion

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for RLAY is Buy with a score of 4.64.

Most Popular

Related Posts